CMV 423

Drug Profile

CMV 423

Alternative Names: RPR CMV 423

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antivirals; Indolizines; Pyridines; Small molecules
  • Mechanism of Action Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cytomegalovirus infections; Herpesvirus infections

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 06 May 2003 Preclinical trials in Herpesvirus infections in France (unspecified route)
  • 06 May 2003 A preclinical study has been added to the Viral Infections antimicrobial activity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top